首頁 > 市場調查報告書 > 醫療設備

透析設備

市場調查報告書

商品編碼

2029975

全球血液淨化設備市場：按模式、應用/臨床適應症、最終用戶和地區分類－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Blood Purification Equipment Market: By Modality, Application/Clinical Indication, End-User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

出版日期: 2026年04月08日 | 出版商:

Astute Analytica | 英文 290 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2025年，血液淨化設備市場價值約為206.8億美元，預計到2035年將達到約401.1億美元，在2026年至2035年的預測期內，複合年成長率將達到6.85%。這一穩定成長的趨勢反映了全球對先進體外療法在慢性腎臟病和急性腎臟病治療中日益成長的依賴，以及醫療保健和重症監護基礎設施的整體改善。

推動市場擴張的主要因素是慢性腎臟病（CKD）盛行率的不斷上升，而糖尿病、高血壓、肥胖以及與老齡化相關的身體機能下降等全球性挑戰導致CKD盛行率持續攀升。隨著CKD進展至末期腎功能衰竭，患者需要長期腎臟替代治療，例如透析，這使得醫院和專業透析中心對血液淨化系統的需求持續不斷。

顯著的市場趨勢

血液淨化設備市場的競爭格局呈現出領導企業高度整合的態勢，同時，尋求革新現有產業結構的創投公司也施加了越來越大的壓力。費森尤斯醫療、百特國際、貝朗和日機裝等大型跨國公司憑藉著大規模、垂直整合的經營模式以及與醫院和透析網路建立的長期合作關係，維持著其市場主導地位。

這些老牌巨頭正集中戰略力量，在鞏固現有市場佔有率的同時，向以價值為導向的醫療生態系統轉型。這包括將數位健康平台、遠端監測功能和數據驅動的臨床管理工具整合到其產品線中，從而更好地適應不斷變化的報銷模式和以結果為導向的醫療保健框架。

同時，旭化成醫療和東麗等專業製造商在一些細分但重要的領域，特別是高流量透析器和先進的血液分離濾芯領域，並繼續保持著強勁的地位。憑藉其在膜技術和過濾科學方面的專業知識，它們在現代血液淨化療法所必需的高性能耗材領域保持著領先地位。

關鍵成長要素

全球人口老化是推動血液淨化設備市場需求成長的主要結構性因素。日本、西歐和北美等地區人口的持續老化與糖尿病、高血壓和心血管疾病等導致腎功能障礙的慢性合併症盛行率上升密切相關。因此，老年人罹患末期腎病的風險顯著升高，需要長期腎臟替代治療（如透析）的患者數量也在增加。

新機會的趨勢

人工智慧（AI）和機器學習的融合正成為血液淨化設備市場一項重要的技術變革驅動力。現代血液透析系統擴大在其軟體中整合複雜的演算法，尤其用於即時處理從血容量監測感測器獲取的生理數據。這些智慧系統能夠辨識治療過程中細微的血流動力學變化，並動態調整超過濾率以維持血流動力學的穩定性。

最佳化障礙

儘管市場需求強勁，但血液淨化設備製造商的經營環境正日益受到嚴重的供應鏈中斷和原料採購挑戰的限制。對於連續性腎臟替代療法 (CRRT) 設備和家用血液透析設備等先進系統的生產而言，這項挑戰尤其突出。這些設備依賴高度精密的電子元件來實現精確的液體容量控制、壓力調節和泵浦校準。由於這些系統需要專用微晶片來確保即時監測和精度，因此它們特別容易受到全球半導體供應波動的影響。

市場動態和趨勢
- 成長要素
- 抑制因子
- 機會
- 主要趨勢
市場規模及預測，2020-2035年
- 按模式
  - 關鍵見解
    - 血液透析（HD）
      - 透析器（血液透析過濾器）
      - 血管和導管套裝
      - 動靜脈瘻管針
      - 透析液連接器和濾芯
      - 滴液室
      - 肝素輸液管/注射器套裝
      - 在線過濾器/空氣捕集器
    - 連續性腎臟替代療法（CRRT）
      - 血液濾過器（CRRT濾過器）
      - CRRT管組/迴路
      - 置換液/透析液袋
      - 通路導管（雙腔/三腔）
      - 閃光燈套件/底火套裝
      - 壓力監測管路組
      - 抗凝血藥筒/管
    - 血液灌注
      - 血液灌流濾芯（樹脂/活性碳）
      - 吸附柱連接器
      - 採血管套裝
      - 預裝抗凝血劑套裝
      - 啟動/沖洗套裝
      - 氣泡捕集器和壓力感測器
    - 血漿置換/血漿分離術（TPE/TPA）
      - 等離子過濾器（等離子分離器）
      - 血漿分離試劑盒
      - 管路和恢復袋
      - 返回篩選器
      - 更換液套裝
      - 抗凝血輸液套裝
    - 免疫吸附
      - 吸附柱（例如，蛋白A柱）
      - 特殊免疫複合物過濾器
      - 封閉式系統用管材和濾芯
      - 細胞激素過濾器
      - 更換液體注入裝置
    - 其他/混合模式
      - 混合治療方案（例如，CRRT + 血液灌流）
      - 多功能血液過濾器
      - 抗凝血劑給藥套裝
      - 連接器、蓋子、魯爾鎖
      - 底漆套裝和閃光燈套件
- 用途/臨床適應症
  - 關鍵見解
    - 急性腎損傷（AKI）
    - 慢性腎臟病/末期腎功能衰竭
    - 敗血症和敗血性休克
    - 感染疾病
    - 自體免疫疾病與神經系統疾病
      - Guillain-Barré二氏症候群
      - 重症肌無力
      - 多發性硬化症
      - 狼瘡性腎炎
      - 戒毒/藥物過量
    - 其他
      - 移植後護理
      - 肝臟支持療法
      - 兒童及新生兒血液淨化
- 最終用戶
  - 關鍵見解
    - 醫院（綜合醫院和專科醫院）
    - 透析中心
    - 重症監護室/危重症病房
    - 門診手術中心
    - 居家醫療環境
- 按地區
  - 關鍵見解
    - 北美洲
      - 美國
      - 加拿大
      - 墨西哥
    - 歐洲
      - 西歐
        
        英國
        德國
        法國
        義大利
        西班牙
        其他西歐國家
      - 東歐
        
        波蘭
        俄羅斯
        其他東歐國家
    - 亞太地區
      - 中國
      - 印度
      - 日本
      - 韓國
      - 澳洲和紐西蘭
      - ASEAN
        
        印尼
        馬來西亞
        泰國
        新加坡
        其他東南亞國協
      - 其他亞太國家
    - 中東和非洲
      - UAE
      - 沙烏地阿拉伯
      - 南非
      - 其他中東和非洲國家
    - 南美洲
      - 阿根廷
      - 巴西
      - 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

Aethlon Medical, Inc.
Asahi Kasei Medical Co., Ltd.
B. Braun Melsungen AG
Baxter International Inc.
Cerus Corporation
CytoSorbents Corporation
ExThera Medical Corporation
Fresenius Medical Care AG & Co. KGaA
Guangzhou Baiyunshan Biomedical
Haemonetics Corporation
Jafron Biomedical Co., Ltd.
JMS Co., Ltd.
Kaneka Corporation
Kawasumi Laboratories Inc.
Medtronic plc
Nikkiso Co., Ltd.
Nipro Corporation
Terumo Corporation
Toray Medical Co., Ltd.
Other Prominent Players

第12章附錄

簡介目錄

Product Code: AA04261755

The blood purification equipment market was valued at approximately USD 20.68 billion in 2025 and is projected to reach around USD 40.11 billion by 2035, expanding at a compound annual growth rate (CAGR) of 6.85% over the forecast period from 2026 to 2035. This steady growth trajectory reflects the increasing global reliance on advanced extracorporeal therapies for managing both chronic and acute renal conditions, alongside broader improvements in healthcare access and critical care infrastructure.

A key underlying driver of this expansion is the rising prevalence of Chronic Kidney Disease, which continues to escalate due to the global burden of diabetes, hypertension, obesity, and aging-related physiological decline. As CKD progresses to end-stage disease, patients require long-term renal replacement therapies such as dialysis, creating sustained and recurring demand for blood purification systems across hospitals and specialized dialysis centers.

Noteworthy Market Developments

The competitive landscape of the blood purification equipment market is characterized by a high degree of consolidation at the top, alongside increasing pressure from venture-backed innovators seeking to disrupt established industry structures. Leading multinational players such as Fresenius Medical Care, Baxter International, B. Braun, and Nikkiso maintain dominant positions through extensive economies of scale, vertically integrated business models, and long-standing contractual relationships with hospitals and dialysis networks.

These established players are increasingly focusing their strategic efforts on protecting existing market share while simultaneously transitioning toward value-based care ecosystems. This includes integrating digital health platforms, remote monitoring capabilities, and data-driven clinical management tools into their product offerings, allowing them to align more closely with evolving reimbursement models and outcome-based healthcare frameworks.

At the same time, specialized manufacturers such as Asahi Kasei Medical and Toray Industries continue to hold strong positions in niche but critical segments, particularly high-flux dialyzers and advanced apheresis cartridges. Their expertise in membrane technology and filtration science allows them to maintain leadership in high-performance consumables that are essential to modern blood purification therapies.

Core Growth Drivers

The aging of the global population is a major structural driver accelerating demand in the blood purification equipment market. The steady "graying" of societies, particularly in regions such as Japan, Western Europe, and North America, is closely associated with a higher prevalence of chronic comorbidities that contribute to kidney dysfunction, including diabetes, hypertension, and cardiovascular disease. As a result, older populations exhibit a significantly increased risk of developing End-stage Renal Disease, thereby expanding the long-term patient pool requiring renal replacement therapies such as dialysis.

Emerging Opportunity Trends

The integration of Artificial Intelligence and machine learning has emerged as the primary technological disruptor in the blood purification equipment market. In modern hemodialysis systems, advanced algorithms are increasingly embedded into device software to process continuous physiological data in real time, particularly from blood volume monitoring sensors. These intelligent systems are capable of identifying subtle hemodynamic trends during treatment sessions and dynamically adjusting ultrafiltration rates to maintain hemodynamic stability.

Barriers to Optimization

Despite robust demand, the operational landscape for manufacturers in the blood purification equipment market is increasingly constrained by significant supply chain disruptions and material sourcing challenges. This friction is especially pronounced in the production of advanced systems such as Continuous Renal Replacement Therapy (CRRT) devices and home hemodialysis machines, which depend on highly sophisticated electronic components for precise fluid control, pressure regulation, and pump calibration. These systems require specialized microchips to ensure real-time monitoring and accuracy, making them particularly vulnerable to global semiconductor supply fluctuations.

Detailed Market Segmentation

By type, the dialysis segment continues to hold the largest market share in the blood purification equipment market, reflecting its indispensable role in managing advanced kidney failure across global healthcare systems. This dominance is primarily driven by the substantial epidemiological burden of End-stage Renal Disease, which necessitates sustained and structured treatment rather than episodic intervention. As a result, dialysis remains the cornerstone therapy for patients who have progressed beyond conservative management options, ensuring consistently high demand for both equipment and associated consumables.

By product, the portable segment accounted for more than 82% of revenue share in the blood purification equipment market, reflecting a clear structural shift in how dialysis and related therapies are being delivered globally. Rather than being an anomaly, this dominance is closely linked to the accelerating adoption of Home Hemodialysis (HHD) and the expanding use of point-of-care solutions for acute and critical care settings. Portable blood purification systems have become increasingly central to modern renal care strategies because they enable treatment delivery outside traditional hospital dialysis units, offering greater flexibility and scalability in both developed and emerging healthcare systems.

By modality, the hemodialysis (HD) segment is projected to have held a dominant position in the blood purification equipment market in 2025. This leadership is largely attributed to its long-established role as the default standard of care for patients with advanced kidney dysfunction, particularly those suffering from Chronic Kidney Disease. Hemodialysis has been integrated into healthcare systems for decades, resulting in well-developed clinical infrastructure, trained personnel, and standardized treatment protocols across hospitals and dedicated dialysis centers. As a result, it remains the most widely accessible and operationally scalable modality for managing end-stage renal disease patients compared to alternative approaches.

By application, the renal disease application segment is anticipated to generate the highest revenue over the forecast period. This dominance is primarily driven by the persistent and irreversible nature of conditions such as Chronic Kidney Disease and end-stage renal failure, which require ongoing and often lifelong therapeutic interventions. Unlike acute conditions that may be treated and resolved, renal failure creates a continuous demand cycle for dialysis and related blood purification procedures, ensuring steady utilization of equipment across hospitals, specialized nephrology centers, and standalone dialysis clinics.

Segment Breakdown

By Modality

Hemodialysis (HD)
Dialyzers (Hemodialysis filters)
Bloodlines and Tubing Sets
AV Fistula Needles
Dialysate Connectors and Cartridges
Drip Chambers
Heparin Lines / Syringe Sets
Inline Filters / Air Traps
Continuous Renal Replacement Therapy (CRRT)
Hemofilters (CRRT filters)
CRRT Tubing Sets / Circuits
Replacement Fluid / Dialysate Bags
Access Catheters (Double/Triple Lumen)
Flush Kits / Priming Sets
Pressure Monitoring Line Sets
Anticoagulation Cartridges / Lines
Hemoperfusion
Hemoperfusion Cartridges (Resin/Charcoal)
Adsorber Column Connectors
Blood Tubing Sets
Prefilled Anticoagulant Kits
Priming / Rinse Sets
Bubble Traps & Pressure Sensors
Plasma Exchange / Apheresis (TPE / TPA)
Plasma Filters (Plasma Separators)
Plasma Separation Kits
Tubing and Collection Bags
Return Filters
Replacement Fluid Sets
Anticoagulation Infusion Kits
Immunoadsorption
Adsorber Columns (e.g., Protein A)
Specialized Immune Complex Filters
Closed-System Tubing and Cartridges
Cytokine Filters
Replacement Fluid Infusion Sets
Others / Hybrid Modalities
Hybrid Therapy Kits (e.g., CRRT + Hemoperfusion)
Multi-functional Blood Filters
Anticoagulation Delivery Kits
Connectors, Caps, Luer Locks
Priming Sets and Flush Kits

By Application / Clinical Indication

Acute Kidney Injury (AKI)
Chronic Kidney Disease / End-Stage Renal Disease
Sepsis and Septic Shock
Infectious Diseases
Autoimmune & Neurological Disorders
Guillain-Barre Syndrome
Myasthenia Gravis
Multiple Sclerosis
Lupus Nephritis
Toxin Removal / Drug Overdose
Others
Post-transplantation care
Liver support therapy
Pediatric and neonatal blood purification

By End-User

Hospitals (General & Specialty)
Dialysis Centers
ICUs / Critical Care Units
Ambulatory Surgical Centers
Home-care Settings

By Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
South Korea
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
Saudi Arabia
South Africa
UAE
Rest of MEA
South America
Argentina
Brazil
Rest of South America

Geography Breakdown

North America is expected to maintain a dominant position throughout the 2026-2035 period, supported by a combination of strong policy frameworks, advanced healthcare infrastructure, and high levels of investment activity across the renal care ecosystem. The region's leadership is closely tied to the proactive role of the U.S. Centers for Medicare & Medicaid Services, which continues to promote and incentivize value-based kidney care models. These initiatives are designed to improve patient outcomes while simultaneously controlling long-term treatment costs, encouraging providers to adopt integrated and outcome-driven care pathways for chronic kidney disease and end-stage renal disease management.
In addition to supportive reimbursement structures, the market strength in North America is reinforced by the dense presence of Tier-1 original equipment manufacturers that continuously introduce technologically advanced dialysis systems and related renal care solutions. This competitive landscape accelerates innovation, improves device accessibility, and strengthens supply chains across both in-center and home-based treatment settings. The region also benefits from a mature regulatory environment that facilitates relatively faster adoption of next-generation therapies compared to many other global markets.

Leading Market Participants

Aethlon Medical, Inc.
Asahi Kasei Medical Co., Ltd.
B. Braun Melsungen AG
Baxter International Inc.
Cerus Corporation
CytoSorbents Corporation
ExThera Medical Corporation
Fresenius Medical Care AG & Co. KGaA
Guangzhou Baiyunshan Biomedical
Haemonetics Corporation
Jafron Biomedical Co., Ltd.
JMS Co., Ltd.
Kaneka Corporation
Kawasumi Laboratories Inc.
Medtronic plc
Nikkiso Co., Ltd.
Nipro Corporation
Terumo Corporation
Toray Medical Co., Ltd.
Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Blood Purification Equipment Market

Chapter 2. Research Methodology & Research Framework

2.1. Research Objective
2.2. Product Overview
2.3. Market Segmentation
2.4. Qualitative Research
- 2.4.1. Primary & Secondary Sources
2.5. Quantitative Research
- 2.5.1. Primary & Secondary Sources
2.6. Breakdown of Primary Research Respondents, By Region
2.7. Assumption for Study
2.8. Market Size Estimation
2.9. Data Triangulation

Chapter 3. Global Blood Purification Equipment Market Overview

3.1. Industry Value Chain Analysis
- 3.1.1. Raw Material & Component Sourcing
- 3.1.2. Product Design & R&D
- 3.1.3. Manufacturing & Assembly
- 3.1.4. Quality Assurance & Regulatory Compliance
- 3.1.5. Distribution & Logistics
- 3.1.6. Sales, After-Sales Service & Clinical Support
3.2. Industry Outlook
- 3.2.1. Sepsis Cases in the World
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitutes
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
3.5. Market Growth and Outlook
- 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
- 3.5.2. Price Trend Analysis, By Modality

Chapter 4. Global Blood Purification Equipment Market Analysis

4.1. Competition Dashboard
- 4.1.1. Market Concentration Rate
- 4.1.2. Company Market Share Analysis (Value %), 2025
- 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Blood Purification Equipment Market Analysis

5.1. Market Dynamics and Trends
- 5.1.1. Growth Drivers
- 5.1.2. Restraints
- 5.1.3. Opportunity
- 5.1.4. Key Trends
5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 5.2.1. By Modality
  - 5.2.1.1. Key Insights
    - 5.2.1.1.1. Hemodialysis (HD)
      - 5.2.1.1.1.1. Dialyzers (Hemodialysis filters)
      - 5.2.1.1.1.2. Bloodlines and Tubing Sets
      - 5.2.1.1.1.3. AV Fistula Needles
      - 5.2.1.1.1.4. Dialysate Connectors and Cartridges
      - 5.2.1.1.1.5. Drip Chambers
      - 5.2.1.1.1.6. Heparin Lines / Syringe Sets
      - 5.2.1.1.1.7. Inline Filters / Air Traps
    - 5.2.1.1.2. Continuous Renal Replacement Therapy (CRRT)
      - 5.2.1.1.2.1. Hemofilters (CRRT filters)
      - 5.2.1.1.2.2. CRRT Tubing Sets / Circuits
      - 5.2.1.1.2.3. Replacement Fluid / Dialysate Bags
      - 5.2.1.1.2.4. Access Catheters (Double/Triple Lumen)
      - 5.2.1.1.2.5. Flush Kits / Priming Sets
      - 5.2.1.1.2.6. Pressure Monitoring Line Sets
      - 5.2.1.1.2.7. Anticoagulation Cartridges / Lines
    - 5.2.1.1.3. Hemoperfusion
      - 5.2.1.1.3.1. Hemoperfusion Cartridges (Resin/Charcoal)
      - 5.2.1.1.3.2. Adsorber Column Connectors
      - 5.2.1.1.3.3. Blood Tubing Sets
      - 5.2.1.1.3.4. Prefilled Anticoagulant Kits
      - 5.2.1.1.3.5. Priming / Rinse Sets
      - 5.2.1.1.3.6. Bubble Traps & Pressure Sensors
    - 5.2.1.1.4. Plasma Exchange / Apheresis (TPE / TPA)
      - 5.2.1.1.4.1. Plasma Filters (Plasma Separators)
      - 5.2.1.1.4.2. Plasma Separation Kits
      - 5.2.1.1.4.3. Tubing and Collection Bags
      - 5.2.1.1.4.4. Return Filters
      - 5.2.1.1.4.5. Replacement Fluid Sets
      - 5.2.1.1.4.6. Anticoagulation Infusion Kits
    - 5.2.1.1.5. Immunoadsorption
      - 5.2.1.1.5.1. Adsorber Columns (e.g., Protein A)
      - 5.2.1.1.5.2. Specialized Immune Complex Filters
      - 5.2.1.1.5.3. Closed-System Tubing and Cartridges
      - 5.2.1.1.5.4. Cytokine Filters
      - 5.2.1.1.5.5. Replacement Fluid Infusion Sets
    - 5.2.1.1.6. Others / Hybrid Modalities
      - 5.2.1.1.6.1. Hybrid Therapy Kits (e.g., CRRT + Hemoperfusion)
      - 5.2.1.1.6.2. Multi-functional Blood Filters
      - 5.2.1.1.6.3. Anticoagulation Delivery Kits
      - 5.2.1.1.6.4. Connectors, Caps, Luer Locks
      - 5.2.1.1.6.5. Priming Sets and Flush Kits
- 5.2.2. By Application / Clinical Indication
  - 5.2.2.1. Key Insights
    - 5.2.2.1.1. Acute Kidney Injury (AKI)
    - 5.2.2.1.2. Chronic Kidney Disease / End-Stage Renal Disease
    - 5.2.2.1.3. Sepsis and Septic Shock
    - 5.2.2.1.4. Infectious Diseases
    - 5.2.2.1.5. Autoimmune & Neurological Disorders
      - 5.2.2.1.5.1. Guillain-Barre Syndrome
      - 5.2.2.1.5.2. Myasthenia Gravis
      - 5.2.2.1.5.3. Multiple Sclerosis
      - 5.2.2.1.5.4. Lupus Nephritis
      - 5.2.2.1.5.5. Toxin Removal / Drug Overdose
    - 5.2.2.1.6. Others
      - 5.2.2.1.6.1. Post-transplantation care
      - 5.2.2.1.6.2. Liver support therapy
      - 5.2.2.1.6.3. Pediatric and neonatal blood purification
- 5.2.3. By End User
  - 5.2.3.1. Key Insights
    - 5.2.3.1.1. Hospitals (General & Specialty)
    - 5.2.3.1.2. Dialysis Centers
    - 5.2.3.1.3. ICUs / Critical Care Units
    - 5.2.3.1.4. Ambulatory Surgical Centers
    - 5.2.3.1.5. Home-care Settings
- 5.2.4. By Region
  - 5.2.4.1. Key Insights
    - 5.2.4.1.1. North America
      - 5.2.4.1.1.1. The U.S.
      - 5.2.4.1.1.2. Canada
      - 5.2.4.1.1.3. Mexico
    - 5.2.4.1.2. Europe
      - 5.2.4.1.2.1. Western Europe
        
        5.2.4.1.2.1.1. The UK
        5.2.4.1.2.1.2. Germany
        5.2.4.1.2.1.3. France
        5.2.4.1.2.1.4. Italy
        5.2.4.1.2.1.5. Spain
        5.2.4.1.2.1.6. Rest of Western Europe
      - 5.2.4.1.2.2. Eastern Europe
        
        5.2.4.1.2.2.1. Poland
        5.2.4.1.2.2.2. Russia
        5.2.4.1.2.2.3. Rest of Eastern Europe
    - 5.2.4.1.3. Asia Pacific
      - 5.2.4.1.3.1. China
      - 5.2.4.1.3.2. India
      - 5.2.4.1.3.3. Japan
      - 5.2.4.1.3.4. South Korea
      - 5.2.4.1.3.5. Australia & New Zealand
      - 5.2.4.1.3.6. ASEAN
        
        5.2.4.1.3.6.1.1. Indonesia
        5.2.4.1.3.6.1.2. Malaysia
        5.2.4.1.3.6.1.3. Thailand
        5.2.4.1.3.6.1.4. Singapore
        5.2.4.1.3.6.1.5. Rest of ASEAN
      - 5.2.4.1.3.7. Rest of Asia Pacific
    - 5.2.4.1.4. Middle East & Africa
      - 5.2.4.1.4.1. UAE
      - 5.2.4.1.4.2. Saudi Arabia
      - 5.2.4.1.4.3. South Africa
      - 5.2.4.1.4.4. Rest of MEA
    - 5.2.4.1.5. South America
      - 5.2.4.1.5.1. Argentina
      - 5.2.4.1.5.2. Brazil
      - 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

6.1. Market Dynamics and Trends
- 6.1.1. Growth Drivers
- 6.1.2. Restraints
- 6.1.3. Opportunity
- 6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 6.2.1. Key Insights
  - 6.2.1.1. By Modality
  - 6.2.1.2. By Application / Clinical Indication
  - 6.2.1.3. By End User
  - 6.2.1.4. By Country

Chapter 7. Europe Market Analysis

7.1. Market Dynamics and Trends
- 7.1.1. Growth Drivers
- 7.1.2. Restraints
- 7.1.3. Opportunity
- 7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 7.2.1. Key Insights
  - 7.2.1.1. By Modality
  - 7.2.1.2. By Application / Clinical Indication
  - 7.2.1.3. By End User
  - 7.2.1.4. By Country

Chapter 8. Asia Pacific Market Analysis

8.1. Market Dynamics and Trends
- 8.1.1. Growth Drivers
- 8.1.2. Restraints
- 8.1.3. Opportunity
- 8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 8.2.1. Key Insights
  - 8.2.1.1. By Modality
  - 8.2.1.2. By Application / Clinical Indication
  - 8.2.1.3. By End User
  - 8.2.1.4. By Country

Chapter 9. Middle East & Africa Market Analysis

9.1. Market Dynamics and Trends
- 9.1.1. Growth Drivers
- 9.1.2. Restraints
- 9.1.3. Opportunity
- 9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 9.2.1. Key Insights
  - 9.2.1.1. By Modality
  - 9.2.1.2. By Application / Clinical Indication
  - 9.2.1.3. By End User
  - 9.2.1.4. By Country

Chapter 10. South America Market Analysis

10.1. Market Dynamics and Trends
- 10.1.1. Growth Drivers
- 10.1.2. Restraints
- 10.1.3. Opportunity
- 10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 10.2.1. Key Insights
  - 10.2.1.1. By Modality
  - 10.2.1.2. By Application / Clinical Indication
  - 10.2.1.3. By End User
  - 10.2.1.4. By Country